GoAI
Get started
SANUWAVE Health Inc. logo

SANUWAVE Health Inc.

SNWV

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$4.61

−$0.29 · -5.92%

Aug 21, 4:00 PM ET

SNWV company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

67

Undervalued

Momentum

19

Strong Down

Sentiment

36

Bearish

Risk resilience

28

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

SANUWAVE Health, Inc. is a shockwave technology company, which engages in the development and commercialization of patented noninvasive, biological response activating devices. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body's normal healing processes and regeneration. The company was founded on May 6, 2004 and is headquartered in Eden Prairie, MN.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Morgan C. Frank
Listed since
Oct 18, 2024
Employees
55

Market position

Day range

Current $4.61

52-week range

Current $4.61

Open
$5.0739
Previous close
$4.90
Volume
67.13K
0.39× average
Average volume
174.25K
Average daily volume
Market cap
39.64M USD
Beta
1.5
Market reference 1
50-day average
$7.9084
-41.71% below average
200-day average
$20.0098
-76.96% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
266.55M USD
P/E (TTM)
2.76×
P/B (TTM)
14.23×
P/S (TTM)
0.9×
EV / EBITDA
13.72×
Earnings yield
4.62%
Free cash flow yield
0.76%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
75.20%
Operating margin
1.54%
Net margin
32.60%
Return on equity
729.65%
Return on assets
31.63%
Return on invested capital
19.41%

Financial health

Debt / equity
7.43×
Current ratio
1.38×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends106%-9%-124%-238%Gross margin, FY2021: 61.68%Gross margin, FY2022: 74.13%Gross margin, FY2023: 70.41%Gross margin, FY2024: 75.23%Gross margin, FY2025: 77.11%Operating margin, FY2021: -108.70%Operating margin, FY2022: -53.47%Operating margin, FY2023: -2.65%Operating margin, FY2024: 16.60%Operating margin, FY2025: 11.23%Net margin, FY2021: -209.52%Net margin, FY2022: -61.48%Net margin, FY2023: -126.52%Net margin, FY2024: -96.13%Net margin, FY2025: 26.82%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 61.68%. Gross margin FY2022 74.13%. Gross margin FY2023 70.41%. Gross margin FY2024 75.23%. Gross margin FY2025 77.11%. Operating margin FY2021 -108.70%. Operating margin FY2022 -53.47%. Operating margin FY2023 -2.65%. Operating margin FY2024 16.60%. Operating margin FY2025 11.23%. Net margin FY2021 -209.52%. Net margin FY2022 -61.48%. Net margin FY2023 -126.52%. Net margin FY2024 -96.13%. Net margin FY2025 26.82%.

Income trends

Revenue

44.05M USD+34.98%

Operating income

4.95M USD-8.71%

Net income

11.81M USD+43.19M USD
Income trends across reported periods51.59M USD21.42M USD−8.75M USD−38.91M USDRevenue, FY2021: 13.01M USDRevenue, FY2022: 16.74M USDRevenue, FY2023: 20.4M USDRevenue, FY2024: 32.63M USDRevenue, FY2025: 44.05M USDOperating income, FY2021: −14.14M USDOperating income, FY2022: −8.95M USDOperating income, FY2023: −540K USDOperating income, FY2024: 5.42M USDOperating income, FY2025: 4.95M USDNet income, FY2021: −27.26M USDNet income, FY2022: −10.29M USDNet income, FY2023: −25.81M USDNet income, FY2024: −31.37M USDNet income, FY2025: 11.81M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 13.01M USD. Revenue FY2022 16.74M USD. Revenue FY2023 20.4M USD. Revenue FY2024 32.63M USD. Revenue FY2025 44.05M USD. Operating income FY2021 −14.14M USD. Operating income FY2022 −8.95M USD. Operating income FY2023 −540K USD. Operating income FY2024 5.42M USD. Operating income FY2025 4.95M USD. Net income FY2021 −27.26M USD. Net income FY2022 −10.29M USD. Net income FY2023 −25.81M USD. Net income FY2024 −31.37M USD. Net income FY2025 11.81M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue44.05M USD32.63M USD20.4M USD16.74M USD13.01M USD
Cost of goods sold10.08M USD8.08M USD6.04M USD4.33M USD4.99M USD
Gross profit33.97M USD24.55M USD14.36M USD12.41M USD8.02M USD
Research and development1.35M USD673K USD579K USD567K USD1.1M USD
Selling, general, and administrative26.79M USD17.67M USD13.57M USD20.03M USD20.28M USD
Operating expenses29.02M USD19.13M USD14.9M USD21.36M USD22.17M USD
Interest expense6.25M USD13.64M USD15.62M USD14.13M USD7.1M USD
Depreciation and amortization1.28M USD1.15M USD1.03M USD952K USD1.24M USD
Operating income4.95M USD5.42M USD−540K USD−8.95M USD−14.14M USD
Net income11.81M USD−31.37M USD−25.81M USD−10.29M USD−27.26M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
0.41
FY2025
Latest fiscal-year revenue
44.05M USD
FY2025 · +34.98% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend2.42-5.63-13.68-21.73FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend47.16M34.74M22.32M9.91MFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$54.00

1071.37% upside
Past 12 months12-month forecast

Price history unavailable

High $55.00Average $54.00Low $53.00

Recent analyst actions

1 institution

SNWV news

seekingalpha.com

SANUWAVE Health, Inc. (SNWV) Q2 2026 Earnings Call Transcript

SANUWAVE Health, Inc. (SNWV) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Sanuwave Health Q2 Earnings Call Highlights

Sanuwave Health NASDAQ: SNWV reported second-quarter 2026 revenue of $9.7 million, down 3% from $10.1 million a year earlier, as lower UltraMIST system sales offset continued growth in the company's recurring applicator…

Read source
globenewswire.com

Sanuwave Announces Q2 FY2026 Financial Results

Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025.

Read source
globenewswire.com

Sanuwave Will Host a Conference Call on August 7, 2026 at 8:30 AM (ET) to Present Q2 2026 Financial Results

EDEN PRAIRIE, Minn., July 30, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live…

Read source
globenewswire.com

Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance

EDEN PRAIRIE, Minn., July 13, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today…

Read source
globenewswire.com

Sanuwave Health Updates Second Quarter 2026 Guidance

Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June 16, 2026 (GLOBE…

Read source

Corporate actions

Corporate action history

Stock split

Effective Oct 18, 2024

1:375

SNWV peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SNWV

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.63M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
486.72K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
129.08K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Invesco NASDAQ Future Gen 200 ETF logoInvesco NASDAQ Future Gen 200 ETFQQQS
Market value
33.27K
Weight
0.15%
AUM
22.98M USD
Expense ratio
0.20%
Price / 1D
$45.0826+1.10%

Continue in GoAI

Research SNWV

research.disclaimer